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Disseminated breast tumour cells in sentinel lymph nodes (SNs) were evaluated by quantitative real-time PCR and the sensitivity of
this assay was compared to the routine histological analysis. First, several candidate marker genes were tested for their specificity in
axillary lymph nodes (ALN) of 50 breast cancer patients and 43 women without breast cancer. The marker gene panel selected,
designed to detect the mRNA of CK19, p1B, EGP2 and SBEM, was subsequently applied to detect metastases in 70 SNs that were
free of metastases as determined by standard histological evaluation. Remarkably, seven negative SNs showed increased marker gene
expression, suggesting the presence of (micro) metastases. Four of these seven SNs positive by real-time PCR proved to contain
tumour deposits after careful review of the slides or further sectioning of the paraffin-embedded material. In three PCR positive SNs,
however, no tumour cells were found by haematoxylin and eosin staining (H&E) and immunohistologically analysis. The quantitative
real-time PCR assay with multiple mRNA markers for the detection of disseminated breast cancer cells in SNs thus resulted in an
upstaging of SNs containing metastastic disease of 10% compared to the routine histological analysis. The application of this technique
may be of clinical relevance, as it is suggested that micrometastatic disease in SNs are associated with further nodal non-SN
metastases in breast cancer.
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In breast cancer to date, the axillary lymph node (ALN) status
remains the most valuable individual prognostic factor for disease
course and recurrence (McGuire, 1987; Foster, 1996). Involvement
of lymph nodes and the number of lymph nodes harbouring
metastases at primary diagnosis have an inverse relationship with
the disease prognosis, meaning that patients with lymph nodes free
of metastases have a better outcome (Fisher et al, 1983; Carter et al,
1989; Hellman, 1994; Quiet et al, 1995; Saimura et al, 1999).
However, 20–30% of node-negative patients will develop a relapse
in 5–10 years after diagnosis (Kamby et al, 1991; Hellman, 1994).
In addition, it is known that 20–30% of node-positive patients are
long-term survivors (Rosen et al, 1989; Joensuu et al, 1998). Based
on these obvious shortcomings of the lymph node status, new
procedures and markers are continuously investigated with regard
to their prognostic value. Recently, it was shown that primary
tumours themselves already contain a gene expression profile that
is strongly predictive of metastasis and poor survival (van de
Vijver et al, 2002; van’t Veer et al, 2002), thereby challenging
treatment choice based on routine prognostic markers in the
future. However, until gene-expression profiling will increasingly
be used for clinical decision-making, the nodal status remains a
main prognostic factor.
Until recently, the standard treatment for patients with operable
breast cancer included the complete dissection of 10–30
ALN. More than half of these patients were found to have
metastases-free lymph nodes and thus had been subjected to
unnecessary surgical risks and complications (Giuliano et al,
1997). A less invasive method for the assessment of lymph node
status is the sentinel lymph node biopsy (SLNB). Thereby,
the lymphatic route of tumour cells to the lymph node(s)
that primarily drains the tumour and most likely harbours
metastatic disease are mapped (Giuliano et al, 1994). The sentinel
lymph node (SN) is highly predictive of the histo-pathology of the
remaining lymphatic basin and can accurately predict axillary
nodal status in at least 98% of cases (Giuliano et al, 1995, 1997).
Furthermore, the SN biopsy allows a more extensive and focused
search for metastases in one or two nodes, in contrast to the
present limited analysis of the multiple lymph nodes from a
complete dissection. Multiple step sectioning and immunohisto-
chemistry staining of the SN increases the accuracy of axillary
staging in breast cancer patients compared with axillary lymph
node dissection (ALND) plus routine histo-pathologic examination
of lymph nodes (Giuliano et al, 1995). In this way additional
micrometastases are identified, which may relate to prognosis
(Bourez and Rutgers, 2001; Tjan-Heijnen et al, 2001). The SN
procedure therewith provides an accurate and feasible alternative
for complete ALND as a staging tool in breast cancer and can
prevent lymph node negative women from unnecessary surgery
(Bourez et al, 2002).
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is used for the detection of metastases in SNs. We have examined
several candidate marker genes, with particular emphasis
on sensitivity and specificity of these genes in ALN of
patients with and without metastases. Finally, a marker panel
of four genes comprising cytokeratin 19 (CK19), trefoil
factor-3 (p1B), epithelial glycoprotein-2 (EGP-2) and small breast
epithelial mucin (SBEM) was used to compare the quantitative
real-time PCR detection method to the routine analysis of SNs,
including multiple step sectioning and immunohistochemical
staining.
MATERIAL AND METHODS
Axillary and SN specimens from breast cancer patients
Axillary (n¼50) and SNs (n¼89) of breast cancer patients were
selected from the fresh-frozen tissue bank of the Netherlands
Cancer Institute/Antoni van Leeuwenhoek hospital (NKI/AvL). As
negative controls 43 ALNs were obtained from patients without
breast cancer undergoing a preventive breast ablation or a lymph
node biopsy for analysis of lymphoma. The latter group was
classified to have benign enlarged lymph nodes. The SN procedure
was introduced in 1996 at the NKI/AvL (Rutgers et al, 1998) and
since then performed on more than 700 patients. The SN was
removed after localisation of the node by combination of
radioactivity measurement by a gamma detection probe (Neo-
probe 100/1500, Neoprobe Corporation, Dublin, UK) exploiting
the remaining activity after preoperative lymphoscintigraphy, and
visually by peroperative injection of Patent Blue V (Blue Patente V;
Laboratoire Guerbet, Aulnay-sous-Bois, France) (Doting et al,
2000).
The ALNs obtained at preventive breast ablation and the
lymph nodes retrieved from analysis of lymphoma were bisected,
snap frozen in liquid nitrogen and stored at  801C. SNs
were subjected to frozen section evaluation. Sentinel lymph
nodes up to 0.5cm were completely embedded in Tissue
Tek (Sakura Finetek, Zoeterwoude, The Netherlands), larger
SNs were bisected or lamellated in slices of 0.2cm and separately
sectioned. Frozen section cutting was aimed at obtaining a
complete cross section at a single level and preventing tissue
loss. Before the frozen section procedure, the microtome was
carefully cleaned to avoid contamination; all lost tissue
was collected and stored at  801C. The amount of lost
tissue varied, and was estimated at least 20 sections of
10mm. Remaining SN tissue was examined after formalin fixation
and paraffin embedding by haematoxylin and eosin (H&E)
staining and immunohistochemistry at three levels (150mm
distance). CAM 5.2 (Becton Dickinson, San Jose, USA) was used
as antibody.
RNA isolation and quantitative real-time PCR
RNA was isolated from 30 tissue sections of 30mm thickness made
from each axillary node, and from the lost frozen tissue of the SNs,
using RNAzol B (Campro Scientific, Amersfoort, The Nether-
lands). In total, 1mg total RNA was used for cDNA synthesis
(20ml), as described previously (Lambrechts et al, 1999).
Based on the published genomic sequences of CK19, p1B, EGP-
2, PS2, mammaglobin and SBEM, the sequences of the real-time
quantitative PCR primers (Sigma Genosys, Cambridge, UK) and of
the 50-fluorescently FAM labelled probes (Applied Biosystems,
Nieuwerkerk a/d IJssel, The Netherlands) were selected using the
Perkin-Elmer Primer Express
s software (PE, Foster City, USA)
(Table 1). All primers were designed to be intron-spanning to
preclude amplification of genomic DNA. To normalise relative
levels of expression, commercially available primers and probes
for the housekeeping genes, glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) and b-actin were used (Applied Biosystems).
Serially diluted cDNA synthesised from RNA isolated and
pooled from 6 10
6 cells of five breast cancer cell lines (MCF7,
CAMA, T47D, MPL13, SkBr3 (American Tissue Culture Collection,
Rockville, USA)), respectively, was used to generate standard
curves for control and marker gene expression. For all cDNA
dilutions, the fluorescence was detected from 0 to 50 PCR cycles
for the control and marker gene in singleplex reactions and
resulted in the CT-value for each cDNA dilution and each target
(CT-value (threshold cycle): the PCR cycle at which a significant
increase in fluorescence is detected, due to the exponential
accumulation of PCR products, represented in arbitrary units
(TaqMan Universal PCR Master Mix Protocol, Applied Biosys-
tems) (Bieche et al, 1999). The quantities found for the GAPDH
control and marker gene were used to calculate the relative
quantity of control and marker gene expression in ALN and SNs.
The second control gene, b-actin, was only used for the
confirmation of GAPDH expression. Each experiment was
performed in triplicate. The quality control of the PCR reactions
was assessed by standardised PCR conditions, including in each
experiment a genomic DNA control and a negative nontemplate
control.
Statistics
The QDA score function, as defined earlier (Bosma et al, 2002),
was calculated from the expression levels of the six marker genes
CK19, p1B, EGP-2, SBEM, PS2 and mammaglobin tested, in
different combinations. QDA is a statistical technique to find the
combination of quadratic and linear functions of variables (e.g.
marker genes), which leads to an optimal separation between
groups (e.g. tumour cell positive and negative lymph nodes). It is a
generalisation of the more familiar Fisher’s Linear Discrimination
Analysis (LDA), which allows only linear functions. QDA performs
Table 1 Primer and probe sequences of each breast cancer marker gene for real-time PCR amplification. All sequences are written 50-30
Marker gene Genbank accession no. Primers Probe (50FAM-30TAMRA)
p1B (L15203) Sense: CTGAGGAGTACGTGGGCCTG CTGCAAACCAGTGTGCCGTGCC
Antisense: AGTCCACCCTGTCCTTGGC
PS2 (X00474) Sense: GAGGCCCAGACAGAGACGTG CTGCTGTTTCGACGACACCGTTCG
Antisense: CCCTGCAGAAGTGTCTAAAATTCA
CK19 (NM002276) Sense: CTACAGCCACTACTACACGAC CACCATTGAGAACTCCAGGATTGTCCTGC
Antisense: CAGAGCCTGTTCCGTCTCAAA
EGP2 (M32306) Sense: CAGTTGGTGCACAAAATACTGTCA TTGCTCAAAGCTGGCTGCCAAATGTT
Antisense: CCATTCATTTCTGCCTTCATCA
SBEM (AF414087) Sense: CTCTTGGGGAGTTTTCCATCTTTCTG CCCAGAATCCGACAACAGCTGCTCC
Antisense: CTTCATCATCAGCAGGACCAGTAG
MaGl (AF015224) Sense: TTCTTAACCAAACGGATGAAACTCT TGCTGTCATATATTAATTGCATAAACACCTCAACATTG
Antisense: GGTCTTGCAGAAAGTTAAAATAAATCAC
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means of the variables but also with respect to standard deviations
and/or correlations. A positive discriminant score of the four
marker genes selected, CK19, p1B, EGP-2 and SBEM, indicates the
presence of breast tumour cells, a negative discriminant score
indicates the absence of tumour cells. The discriminant threshold
score separating these two groups is zero.
Sensitivity
A cDNA pool of three tumour cell positive ALNs was diluted 1:10,
1:100, 1:1000, 1:10000 and 1:100000 in a cDNA pool of three
control ALNs. For all cDNA dilutions the fluorescence was
detected from 0 to 50 PCR cycles, for each individual marker
gene in triplicates. The CT-values obtained were compared to
serially diluted cDNA synthesised from RNA isolated from 5000
MCF7 cells. The dilution of MCF7 RNA of 1:10, 1:100, 1:1000,
1:10000 and 1:100000 corresponds to the total RNA amount
obtained from 500, 50, 5, 0.5 and 0.05 MCF7 cells, respectively. All
standard curves for these experiments were generated using the
cell line mix as described for the marker and control gene real-time
PCR reactions.
RESULTS
Marker gene selection for the detection of metastatic
breast tumour cells in ALN
Several potential marker genes were tested to determine genes that
are highly expressed in 50 ALNs of breast cancer patients with
pathological verified tumour involvement, but that are at the same
time expressed at low levels in 43 ALNs of women without
evidence of breast cancer. Gene expression was quantitated for the
four breast cancer marker genes CK19, PS2, EGP-2 and p1B, which
we used earlier for the detection of circulating tumour cells in
peripheral blood of breast cancer patients (Bosma et al, 2002).
Furthermore, the genes mammaglobin, epidermal growth factor
receptor (EGFR) and SBEM were tested, described in the literature
as breast cancer marker genes (De Luca et al, 2000; Mitas et al,
2001; Miksicek et al, 2002; Zehentner et al, 2002). For each gene,
CT-values for negative control lymph nodes and metastatic breast
cancer lymph nodes were obtained from triplicate reactions. For all
ALN samples, the expression level for each of the marker genes
relative to the breast cancer cell line mix standard curve was
calculated and corrected for the input of cDNA based on the
GAPDH control (see Materials and Methods) (Table 2).
We observed that the median expression levels of EGFR were
higher in the control ALNs than in the tumour cell positive lymph
nodes (Table 2). Thus, this gene was not useful for the detection of
metastatic breast cancer in lymph nodes, whereas the median
expression levels for CK19, p1B, EGP-2, SBEM, PS2 and
mammaglobin were significantly higher in the ALNs containing
metastatic breast cancer (Table 2), determined by the Mann–
Whitney test (data not shown). To optimally use the expression
levels of these latter marker genes to separate lymph nodes with
and without tumour cell involvement, the quadratic discriminant
analysis (QDA) was employed (Bosma et al, 2002) (see Material
and Methods). A combination of four marker genes was shown to
have the highest specificity in separating tumour cell negative and
positive lymph nodes (data not shown). In the following step, we
tested different combinations of sets of four genes to determine the
marker gene panel that gave the largest discriminant score between
negative and tumour cell positive lymph nodes. The marker set
including CK19, p1B, EGP2 and SBEM gave the largest separation
between breast tumour cell negative and positive ALNs with zero
misclassified normal control lymph nodes (Figure 1). The median
Table 2 Expression levels (quantities) for each housekeeping gene
relative to the standard curve and relative quantities for each marker gene
relative to the standard curve and corrected for the input of cDNA based
on the GAPDH control in arbitrary units (au)
Housekeeping
gene Tissue Median quantity Range
GAPDH ALNneg 0.30000 0.01800–1.85000
ALNpos 0.15500 0.00002–1.90000
b-Actin ALNneg 0.76250 0.09800–2.75000
ALNpos 0.28000 0.00001–1.35000
Marker gene Tissue Median relative quantity Range
CK19 ALNneg 0.00001 0.000003–0.000103
ALNpos 0.04931 0.00022–8.23529
p1B ALNneg 0.01778 0.00009–0.23583
ALNpos 0.13400 0.00017–55.5556
EGP2 ALNneg 0.00035 0.00009–0.00270
ALNpos 0.07300 0.00112–0.69109
SBEM ALNneg 0.00047 0.00011–0.02112
ALNpos 0.07800 0.00073–84.7619
PS2 ALNneg 0.00001 0.00000–0.00026
ALNpos 0.01319 0.00000–10.0457
Mammaglobin ALNneg 0.000001 0.00000–0.00003
ALNpos 0.00014 0.00001–1.16994
EGFR ALNneg 3.06956 0.80620–10.1852
ALNpos 1.45317 0.05461–58.2897
ALNneg¼tumour cell free control axillary lymph nodes; ALNpos¼axillary lymph
nodes harbouring breast tumour cells.
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Figure 1 Discriminant score of expression of the four marker genes
CK19, p1B, EGP2 and SBEM in ALN of patients with and without breast
cancer. The median expression levels for the markergene panel within a
group are indicated by a horizontal line. Closed circles represent breast
cancer patients, open circles women without breast cancer. The discriminant
score separating the two groups is indicated by a dashed line.
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score is 4.05 (range: 1.25–467) and  4.51 (range:  6.97 to  2.79),
respectively (P-value o0.0001). The threshold score discriminat-
ing the two groups is zero. A cross validation also showed a 100%
separation between the tumour cell positive and negative ALNs
(data not shown). These results indicate that the real-time PCR
analysis using a marker panel of genes is specific and at least as
sensitive as the standard histological analysis.
Sensitivity
To define the value of the quantitative real-time PCR analysis for
the detection of metastatic breast cancer cells, we determined the
sensitivity of the marker panel. Working with a solid tissue such as
lymph nodes makes it difficult to dilute breast tumour cells
directly in the tissue like it is usually done for sensitivity assays in
peripheral blood (Kufer et al, 2002). Instead, we pooled cDNA of
three tumour cell positive ALNs and serially diluted this cDNA
corresponding to five log steps in a cDNA pool of three control
ALNs. A real-time PCR was performed for all cDNA dilutions, for
each marker gene individually, and the detection limit of the assay
was defined. To get an indication of how many breast tumour cells
can be detected using the quantitative PCR approach, we
compared the CT-values obtained to those of serially diluted
cDNA synthesise from RNA isolated from 5000 MCF7 cells. The
dilution of 10
 1 up to 10
 5 corresponds to 500 to 0.05 MCF7 cells,
respectively. The standard curves for all experiments were
generated from a pool of five breast cancer cell lines, which
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Figure 2 (A) Standard curves of CK19, p1B, EGP2 and SBEM, used for determining the sensitivity of the marker genes (black circles). Grey circles
represent lymph node samples tested. The threshold cycle (CT-value) is plotted against the starting quantity of a pool of five breast cancer cells lines.
(B) Sensitivity of the markerpanel CK19, p1B, EGP2 and SBEM real-time PCR defined by analysis of serial dilution of a cDNA pool of three tumour cell
positive ALN in a cDNA pool of three control lymph nodes. Subsequently, CT-values obtained were compared to serially diluted MCF7 cDNA, for each
marker gene individually. The detection limit of p1B with regard to the background expression of control lymph nodes corresponds to the amount of 50
MCF7 cells, for SBEM to five MCF7 cells and for CK19 and EGP2 to 0.5 MCF7 cells.
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(Figure 2A). The limit of detection of the cDNA pool of tumour cell
positive lymph nodes diluted in a pool of negative lymph nodes is
shown in Figure 2B for every of the four marker genes individually.
The CT-value of p1B reaches a plateau when less than 50 MCF7
cells are present, indicating that a sensitivity of 50 breast tumour
cells can be reliably detected by this marker. The detection limit
for SBEM corresponds to the presence of five MCF7 cells and for
CK19 and EGP2 to as low as 0.5 MCF7 cells (Figure 2B).
Marker gene expression in SNs
To determine whether real-time PCR analysis was also capable of
detecting metastases in SNs, we analysed 70 SNs without evidence
of metastatic breast tumour cells following standard histological
analysis. The median discriminant score for the tumour cell
negative SNs was, as for the control ALNs, smaller than zero, the
threshold score that separates the tumour cell negative from the
tumour cell positive ALN group. Additionally, 19 histologically
proven positive SNs were analysed using the marker gene panel to
stage the accuracy of the real-time approach. The median
discriminant score is lower compared to the tumour cell positive
ALNs. However, the set of marker genes is still over expressed in
the positive SNs and the discriminant scores of all 19 SN are above
the threshold of zero, indicating the presence of metastatic breast
tumour cells. The marker panel containing CK19, EGP-2, p1B and
SBEM can therefore also be applied for the evaluation of SNs.
Remarkably, the evaluation of the 70 histologically negative SNs
on an individual basis showed for seven SNs a positive
discriminant score of the four mRNA marker genes, indicating
the presence of metastatic tumour cells (Figure 3). Subsequently,
the frozen tissue and paraffin sections of these seven SNs, tumour
cell positive by real-time PCR, were reviewed. The slides of two
cases revealed tumour deposits at review, which were missed at the
first evaluation. In one of these SNs, tumour was present in the
frozen section slide, in the other one in the H&E stained slide of
the first level. In both cases the deposits were cell clusters with a
diameter smaller than 0.2cm (micrometastases). No evidence of
metastases was found in the slides of the standard evaluation of the
SNs of the other five cases. The remaining paraffin-embedded
material of these nodes was completely step sectioned at intervals
of 50mm, stained by H&E and immunohistochemistry and revealed
micrometastases in one case, whereas the other four nodes
remained negative. In one of these latter patients with a tumour
cell negative SN, however, a non-SN removed during the SN
procedure showed to harbour breast tumour cells verified by
standard histological analysis. Therefore, the possibility that the
histologically negative SN also harbours metastatic cells might be
high, as the positive discriminant score of the marker panel
obtained by real-time PCR indicates.
DISCUSSION
In this study, we have established a highly sensitive and
quantitative multimarker real-time PCR approach to detect
disseminated breast cancer cells in ALNs and SNs. Based on
experiences it is unlikely that false positive results can be avoided
if only a single marker gene is used in a RT–PCR based test system
(Lambrechts et al, 1999). Using more than a single marker gene, as
applied in our experiments, is a potential way to overcome the
problem of illegitimate expression (Chelly et al, 1989), assuming
that there is a little chance of encountering significant illegitimate
mRNA of more than one gene at a time.
The marker genes tested, CK19, p1B, EGP-2, SBEM, PS2 and
mammaglobin, share the characteristics that they are all expressed
at high levels in ALNs harbouring metastatic breast tumour cells,
but only at very low levels in lymph node tissue itself (Table 2).
However, EGFR, a mRNA marker gene described for circulating
tumour cell detection in peripheral blood of breast cancer patients
(De Luca et al, 2000), appeared not to be applicable as a marker
gene in lymph nodes due to its high background expression in
control lymph nodes. Applying a discriminant score (QDA)
showed that the marker set including CK19, p1B, EGP2 and SBEM
gave the most significant separation between tumour cell negative
and positive ALNs with zero misclassified control lymph nodes
(Po0.0001).
The expression level for each of the marker genes was calculated
relative to the standard curve and corrected for the input of cDNA
based on the GAPDH control. The standard curves were generated
from a mix of five breast cancer cell lines to assure that every
marker gene tested will be expressed at high levels, therewith
creating reproducible and reliable experiments (Figure 2A). A
single breast cancer cell line as standard shows variation in gene
expression levels of individual marker genes, a noticeable feature
when determining the sensitivity of our marker panel used. The
expression levels of SBEM and p1B in MCF7 cells are distinctly
lower than those of CK19 and EGP2. This might be the reason for
the nonlinear kinetics of the PCR reaction in the sensitivity
experiment (Figure 2B), compared to the linear kinetics in the real-
time PCR assays (Figure 2A), and the establishment of the
amplification plateau below 30 cycles observed for SBEM and p1B.
When applying the set of marker genes to detect (micro)
metastases in SNs, seven of the 70 histologically breast tumour cell
free SNs showed a positive discriminant score, predicting the
presence of metastatic disease. Four of these seven SNs could be
histologically confirmed by more intensive review of slides or
further sectioning of the paraffin-embedded material, what shows
that standard evaluation is false-negative in 4%, whereas in three
SNs no tumour cells were found by H&E staining and
immunohistochemical analysis.
Using a real-time PCR approach we achieve an upstaging of SNs
containing breast cancer metastases of 10% compared to the
standard histological analysis. Our findings are in contrast to the
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Figure 3 Discriminant score of expression of the four marker genes
CK19, p1B, EGP2 and SBEM in ALN of patients with and without breast
cancer, and in histologically negative and positive SN of breast cancer
patients. The median expression levels for the markergene panel within a
group are indicated by a horizontal line. Seven of the 70 histological
negative SN show a positive discriminant score, indicated by a surrounding
black triangle. The discriminant score separating the tumour cell positive
and negative lymph nodes is indicated by a dashed line.
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SNs immunostaining appears to be more sensitive/specific than
quantitative PCR for breast tumour cell detection. The apparent
discrepancy between our results and that of Schroder et al are
likely due to the increased sensitivity achieved by the use of a
multimarker panel in combination with the QDA score.
The follow-up times of the seven patients, whose histo-
logically negative SNs showed a discriminant score predicting
the presence of tumour cells using the real-time PCR approach,
are too short to give an indication whether the upstaging of
SNs reached by quantitative PCR has a prognostic
value. Furthermore, it remains unknown whether micrometastatic
disease in pathology-negative SNs have clinical significance.
Ongoing clinical trials that will address this important issue
(Grube and Giuliano, 2001; Ross, 2001). However, recently it
was suggested that approximately 18% of the SNs harbouring
micrometastases might be associated with further nodal non-SN
metastases (Cserni et al, 2003). Our results provide informa-
tion that could lead to a better management of breast cancer
patients by reducing the rate of false-negative SNs using a
quantitative real-time PCR approach with multiple mRNA markers
instead of standard histological analysis for the detection of
metastases in SNs.
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